设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2023 年第 8 期 第 18 卷

磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白自噬通路在支气管肺发育不良中的作用

The role of phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin autophagy pathway in bronchopulmonary dysplasia

作者:成小蓉刘蕊蕊潘飞飞黄栋

英文作者:Cheng Xiaorong Liu Ruirui Pan Feifei Huang Dong

单位:贵州医科大学附属人民医院贵州省人民医院儿童重症医学科,贵阳550002

英文单位:Department of Pediatric Intensive Care Medicine Affiliated People′s Hospital of Guizhou Medical University Guizhou Provincial People′s Hospital Guiyang 550002 China

关键词:支气管肺发育不良;磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路;自噬;雷帕霉素

英文关键词:Bronchopulmonarydysplasia;Phosphatidylinositol-3-kinase/proteinkinaseB/mammaliantargetofrapamycinpathway;Autophagy;Rapamycin

  • 摘要:
  • 目的 探讨磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/Akt/mTOR)自噬通路在支气管肺发育不良中的作用。方法 将A549细胞(腺癌人类肺泡基底上皮细胞)一定条件培养后分成对照组、支气管肺发育不良组、雷帕霉素干预组。支气管肺发育不良组、雷帕霉素干预组高氧环境培养,置于37 ℃、85%氧气孵化箱中培养48 h,前者不加药剂、后者加10 μmol/L的雷帕霉素干预;对照组常规环境培养,置于37 ℃、5%二氧化碳孵化箱中培养48 h,不加药剂。利用高氧构建支气管肺发育不良的细胞模型,利用蛋白质印迹实验和实时荧光定量聚合酶链反应(RT-qPCR)实验验证自噬对高氧处理后A549细胞肺泡表面标志物合成蛋白复合物(SPC)、水通道蛋白5(AQP5)的影响,利用5-乙炔基-2′-脱氧尿苷(EdU)实验检测自噬对高氧处理后A549细胞增殖的影响,利用蛋白质印迹实验验证PI3K/Akt/mTOR自噬通路在支气管肺发育不良中的作用。结果 蛋白质印迹实验和RT-qPCR实验表明自噬激活剂雷帕霉素挽救了高氧处理后A549细胞SPC、AQP5表达的下调。EdU实验表明雷帕霉素显著促进了高氧处理后A549细胞的增殖,EdU阳性细胞百分比高于支气管肺发育不良组[(0.48±0.06)比(0.36±0.02)](P<0.05)。蛋白质印迹实验显示雷帕霉素干预后的A549细胞中的磷酸化-PI3K、磷酸化-Akt、磷酸化-mTOR、自噬选择性底物P62的表达水平显著降低,微管相关蛋白1轻链3的表达水平显著上升(均P<0.05)。结论 PI3K/Akt/mTOR自噬通路在支气管肺发育不良中发挥着重要作用。

  • Objective To discuss the role of phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin(PI3K/Akt/mTOR) autophagy pathway in bronchopulmonary dysplasia. Methods  A549 cells (adenocarcinoma human alveolar basal epithelial cells) were cultured under certain conditions and divided into control group, bronchopulmonary dysplasia group and rapamycin intervention group. The bronchopulmonary dysplasia group and the rapamycin intervention group were cultured in a hyperoxic environment and incubated at 37 ℃ in an 85% oxygen incubator for 48 h, and the former was not treated with drugs, while the latter was treated with 10 μmol/L of rapamycin intervention. The control group was cultured in a conventional environment and incubated at 37 ℃ in a 5% carbon dioxide incubator for 48 h without drugs. Hyperoxia was used to construct a cell model of bronchopulmonary dysplasia. Western Blotting test and real-time fluorescence quantitative polymerase chain reaction(RT-qPCR) test were used to verify the effect of autophagy on the synthesis of protein complexes (SPC) and aquaporin 5 (AQP5) on alveolar surface markers of A549 cells after hyperoxia treatment. The effect of autophagy on the proliferation of A549 cells after hyperoxia treatment was detected by 5-ethynyl-2′-deoxyuridine (EdU) test. Western Blotting test was used to verify the role of PI3K/Akt/mTOR autophagy pathway in bronchopulmonary dysplasia. Results Western Blotting test and RT-qPCR test showed that autophagy activator rapamycin rescued the down-regulation of SPC and AQP5 expression in A549 cells after hyperoxia treatment. EdU test showed that rapamycin significantly promoted the proliferation of A549 cells after hyperoxia treatment, and the percentage of EdU positive cells was higher than that in the bronchopulmonary dysplasia group[(0.48±0.06) vs (0.36±0.02)](P<0.05). Western Blotting test showed that the expression levels of phosphorylated PI3K, phosphorylated Akt, phosphorylated mTOR and autophagy selective substrate P62 in A549 cells after rapamycin intervention decreased significantly, and the expression level of microtubule associated protein 1 light chain 3 significantly increased(all P<0.05). Conclusions  PI3K/Akt/mTOR autophagy pathway plays an important role in bronchopulmonary dysplasia.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭